glp-1 drug market competition 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 Receptor Agonist Market Size
Description
[32] Lim GE, et al
By July 31, 2025, the FDA had received 605 reports of adverse events tied to compounded semaglutide and 545 reports related to compounded tirzepatide
Clinical trials have also noted rare cases of thyroid cancer associated with these drugs.
36,37,38 Different GLP-1RA use between studies may contribute to inconsistent findings across the studies
Sci Rep 11 , 9167 (2021)
